A research study focusing on magic mushrooms in Canada revealed that nearly 80% of the respondents support the use of psilocybin for medicinal purposes, especially for individuals experiencing distress. Additionally, around two-thirds of these Canadian participants agreed with the idea of making psilocybin legally accessible for those in need.
Besides advocating for easier access to the substance, a considerable 84.8 percent of respondents opined that the public health system should bear the costs of these therapies. A substantial portion of Canadians views psilocybin as a viable treatment, particularly for alleviating end-of-life distress.
[toc]
Key Findings:
- Residents from Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical option for handling end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants from two double-blind trials reported immediate and long-lasting benefits, with impacts enduring for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, occurs when individuals face their mortality. Such patients may undergo feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose in life. This form of distress predominantly impacts patients with life-threatening conditions, potentially resulting in a wish for hastened death or suicidal ideation.
Generally, people grappling with terminal diseases or significant life changes are the ones who most often experience this type of distress. It significantly impairs their mental health and overall life quality.
Existential therapy aims to address problems like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It may necessitate numerous sessions and may not work for everyone.
The ambiguity regarding the effectiveness of such therapy is a primary reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Approach
Over the last two decades, preliminary clinical studies have highlighted the potential advantages of psychedelic substances in addressing complex mental health conditions. Specifically, psilocybin has demonstrated a rapid and sustained reduction of existential distress in individuals facing end-of-life.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision enables healthcare providers to request controlled substances for their patients.
Canadian Support for Access to Psilocybin
An article presented in the Palliative Care Journal evaluates societal viewpoints on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Engagement of 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as an acceptable medical treatment for end-of-life existential distress. 63.3% argue for the integration of psilocybin into medical treatments. 84.8% endorse the public health system’s provision of this therapy. 44.2% hold that healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings align with surveys from Canada, England, and Australia. The researchers underscored the uniqueness of their study, which focuses on using psychoactive substances to alleviate existential distress in end-of-life situations.
Factors for Canadian Advocacy of Psilocybin Use
An increasing number of Canadians are advocating for the application of psilocybin as a treatment, largely attributed to findings from esteemed research institutions. The perceived safety of psilocybin mushrooms in reducing existential distress is another influential factor. Subjects across different studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Rapid and enduring |
| The benefits of this therapy, which can last up to six months or even longer, are primarily due to mystical experiences. These experiences often involve a feeling of unity and profound emotional insights. | ||
| Trial conducted by New York University | 29 patients were randomly selected to either receive psilocybin or the active placebo, niacin. | Results from this study were consistent with the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a new, improved perspective on life and death. |
| BMC Palliative Care | The study involved interviewing nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. The aim of the research was to understand how palliative care professionals perceive existential distress and their opinions on psychedelic therapy as a potential treatment option. | Palliative care practitioners have indicated that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Scientific research is not the only evidence supporting the effectiveness of psilocybin. Numerous patient accounts highlight its potential to boost mental wellbeing and improve overall quality of life.
The Journey of Yokoi
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shared a transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature, and accompanied by imaginary creatures. This vision gives her a profound sense of the universe’s interconnectedness and support, providing her with immense peace and confirmation.
Despite receiving conventional mental health support, Yokoi continued to grapple with severe anxiety and distress following her diagnosis. Psilocybin therapy allowed her to reconnect with her body and provided a tangible sense of love and support. This has significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was an administrative supervisor in healthcare, working full-time when the study was conducted, and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked if her religious or spiritual beliefs had changed since her therapy session, she reported that her experiences had given her beliefs a sense of meaning and reality.
Brenda’s Personal Experience
Throughout her therapeutic sessions, Brenda experienced the sensation of dying twice. After these episodes, she no longer feared death, instead perceiving it as a beautiful part of life’s journey. She attributed her healing from past traumas to the study, a change that was reflected in her data. A decrease in anxiety and death-related fear, coupled with an increase in spirituality, was observed.
Available Options for Magic Mushroom Products in Canada
At present, the accessibility of psilocybin capsules and other products designed for managing existential distress and other mental health conditions may be limited. Nonetheless, reliable online dispensaries can serve as a valuable resource for obtaining these products when needed.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and a few surrounding South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the popular Penis Envy mushrooms of the 1970s. |
| Potency | Moderately potent; ideal for beginners. | Similarly moderate in potency; perfect for those new to this. | Highly potent; best suited for those with some level of experience. |
| Effects | Causes a mental buzz, slight confusion, enhanced color perception, euphoria, spiritual experiences, increased creativity, and sharpened focus. | Leads to an energizing and long-lasting high, minor visual changes, enhanced creativity, euphoria, a gentle physical high, fractal images, and a sense of joy. | Produces profound shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood upliftment. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can create a substantial burden for many patients nearing the end of their life. Traditional methods of managing this distress can sometimes be insufficient, prompting a surge in support for the integration of magic mushrooms in public healthcare within Canada. This growing public interest could
We urge regulatory authorities to acknowledge the potential of magic mushrooms as a feasible treatment option. Acquire your psychedelics and mushroom delivery from Where To Buy Shrooms Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experiences of patients undergoing Psychedelic-assisted therapy (PAT) can significantly differ. Proper preparation and strict adherence to certain procedures are crucial for a successful outcome. It is necessary for patients to go through rigorous screening and mental readiness before ingesting the substance.
- Preparation Prior to the Session: Patients are subjected to an extensive evaluation. The therapist will discuss the patient’s goals and expectations to set the session’s intentions. The therapist will also explain the potential effects of the process and what to expect during the session.
- The Session: A controlled dosage of the substance is given to patients during the session. The session’s environment is kept comfortable and free from distractions to promote relaxation and introspection. The therapist offers ongoing support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps the patient interpret and process their experiences. Follow-up sessions provide continuous support and counselling to reinforce the insights and changes made during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, primarily the 5-HT2A receptor. This interaction can trigger changes in perception, mood, and thought, leading to substantial shifts in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not suitable for everyone. Patients with certain mental health conditions or existential distress are carefully screened to exclude those with a history of psychosis.
Related Articles:
